EC Clinical and Medical Case Reports

Obesity has become an endemic disorder worldwide in the last three decades and with its rise we noticed the rise of the associated comorbidities like insulin resistance, diabetes mellitus, dyslipidemia, non-alcoholic fatty liver disease, polycystic ovaries and others.

With the new medications for obesity, represented by GLP1 receptor agonists, we observed substantial effect on weight loss with more prominent effect of the new medications, semaglutide and tirzepatide.

In my case report I present 3 patients with obesity, with or without complication.

They were put on tirzepatide with regular follow up, looking for the improvement in 3 months on weight status and all metabolic parameters, at the same time if adverse effects were tolerated or not.

 Keywords: Obesity; Insulin Resistance; Diabetes Mellitus; Dyslipidemia; GLP1 Receptor Agonists; Semaglutide and Tirzepatide

1. Louis J Aronne., et al. “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity the SURMOUNT-4 randomized clinical trial”. Journal of the American Medical Association1 (2024): 38-48.
2. Elisa Fabbrini., et al. “Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications”. Hepatology2 (2010): 679-689.
3. Michael EJ Lean., et al. “5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study”. The Lancet Diabetes and Endocrinology 4 (2024): 233-246.
4. Hannah Moll., et al. “GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study”. EClinicalMedicine 73 (2024): 102661.